Mizuho sees Pfizer patent trial as the single largest catalyst for BridgeBio (BBIO) stock this year
Tweet Send to a Friend
Mizuho analyst Salim Syed reiterated an Outperform rating and $106.00 price target on BridgeBio Pharma (NASDAQ: BBIO)The analyst commented, "The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
